Open an account

bioAffinity Technologies

BIAF · NASDAQ

$3.66+$0.2211 (+6.43%)TodayMarket closed ·
Prev close $3.44

About BIAF

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Employees
57
Headquarters
San Antonio, Texas
Listed
Aug 26, 2022
Sector
Health Care
Industry
Biotechnology
Website
bioaffinitytech.com

BIAF key statistics

Market cap
4.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.05M
Volume
33
Open price
$3.44
High today
$3.75
Low today
$3.44
52 Week high
$80.70
52 Week low
$3.23

bioAffinity Technologies (BIAF) at a glance

As of Oct 21, 2026, bioAffinity Technologies (BIAF) shares are priced at $3.66, giving the company a market cap of 4.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.44 and $3.75. The current price is 6.4% above the day's low and 2.4% below its high.

Volume so far is 33 shares, below the average of 2.05M shares a day.

Over the past year bioAffinity Technologies has ranged from $3.23 to $80.70, and now sits 1% of the way up that range.

bioAffinity Technologies met or beat analyst EPS estimates in 1 of the last 6 quarters. In Q3 FY25 it reported -$71.10 per share against an estimate of -$41.31.

BIAF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 6 quarters, by 2.0% on average.

  1. Q2 FY24: reported -$85.50 per share against an estimate of -$78.03
  2. Q3 FY24: reported -$72.00 per share against an estimate of -$68.85
  3. Q4 FY24: reported -$94.50 per share against an estimate of -$64.26
  4. Q1 FY25: reported -$72.00 per share against an estimate of -$73.44
  5. Q2 FY25: reported -$76.50 per share against an estimate of -$45.90
  6. Q3 FY25: reported -$71.10 per share against an estimate of -$41.31

BIAF news

  • Press releaseBusiness Wire

    bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

  • Press releaseBusiness Wire

    bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

  • Press releasePRNewswire

    WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

  • Press releaseBusiness Wire

    bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

  • Press releasePRNewswire

    WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

  • Press releaseBusiness Wire

    bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

  • Press releaseBusiness Wire

    bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm

  • Press releaseBusiness Wire

    bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

Similar companies

Companies in the same industry as bioAffinity Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.